NVSEF - Novartis AG
| Previous Close | 87.33 |
| Open | 87.16 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 86.00 - 87.16 |
| 52 Week Range | 74.46 - 96.50 |
| Volume | 698 |
| Avg. Volume | 29,250 |
| Market Cap | 198.382B |
| Beta (3Y Monthly) | 0.44 |
| PE Ratio (TTM) | 17.67 |
| EPS (TTM) | 4.87 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2018-03-06 |
| 1y Target Est | N/A |
- Reuters
Novartis blames former AveXis executives for Zolgensma data manipulation
Novartis AG blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so. The Kaspar brothers were executives at AveXis, the company that developed the drug and was acquired by Novartis for $8.7 billion last year. Last month, the U.S. Food and Drug Administration said Novartis could face civil or criminal penalties because of the data manipulation and the possibility the company had waited to notify regulators.
- GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG
NEW YORK, Sept. 23, 2019 -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) concerning.
- GlobeNewswire
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Novartis was the subject of an FDA statement issued on August 6, 2019. According to the FDA, the Company had submitted manipulated data for its biologics license application (“BLA”) for its gene therapy drug, Zolgensma.
- Yahoo Finance
Startup uses remittances to remove 'time and distance' from health care
Hoy Health launched less than two years ago, but sees strong growth potential in paving the way to the Latin American health care market.
- GlobeNewswire
Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On August 6, 2019, the U.S. Food and Drug Administration (“FDA”) issued a statement revealing that data submitted in the Company’s biologics license application (“BLA”) for its gene therapy drug, Zolgensma, had been manipulated.
- GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS)
BENSALEM, Pa., Sept. 11, 2019 -- Law Offices of Howard G. Smith continues its investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors.
- GlobeNewswire
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Novartis was the subject of an FDA statement issued on August 6, 2019. According to the FDA, the Company had submitted manipulated data for its biologics license application (“BLA”) for its gene therapy drug, Zolgensma.
- Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
- Business Wire
ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
- GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS
NEW YORK, Sept. 05, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
- GlobeNewswire
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Novartis was the subject of an FDA statement issued on August 6, 2019. According to the FDA, the Company had submitted manipulated data for its biologics license application (“BLA”) for its gene therapy drug, Zolgensma.
- Reuters
Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments. Novartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday agreed to license from Poland's Polpharma Biologics a version of Biogen's decade-old Tysabri for multiple sclerosis. This is the fifth proposed biosimilar licensed by Sandoz in nine months.
- Reuters
China expands drug bulk-buy programme, puts pressure on pharma firms
China has expanded a pilot drug bulk-buying programme to the entire country in an attempt to negotiate lower prices from drug manufacturers, heaping fresh pressure on multinational pharmaceutical companies and their domestic rivals. The programme rolled out last year saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process to bulk-buy 25 types of drugs.
- ACCESSWIRE
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG (NVS)
NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG (“Novartis” or the Company”) (NASDAQ: NVS) . Investors ...
- Reuters
Novartis takes aim at Roche's star MS drug
Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.
- ACCESSWIRE
IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 29, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” ...
- GlobeNewswire
EQUITY ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Novartis AG – NVS
NEW YORK, Aug. 29, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
- ACCESSWIRE
NVS LOSS NOTICE: Rosen, a Globally Recognized Law Firm, Announces Investigates Securities Claims Against Novartis AG - NVS
New York, NY / ACCESSWIRE / August 25, 2019 / Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) ...
- ABC News Videos
Distribution of heartburn drug Zantac halted over possible carcinogen
The FDA learned of small amounts of a carcinogen in some branded and generic products.
